A Full-Circle Approach To
Treating Disease
Pipeline
Orna’s in situ CAR therapy (isCAR™) combines oRNA™ technology with our proprietary LNPs to create modified immune cells within a patient, no lymphodepletion required. Unlike existing ex vivo CAR-T therapies, our isCAR™ program generates CAR-T, CAR-NK and CAR-Mac cells at once, and is truly off-the-shelf. This easily redosable format allows for reliable dose control and consistent generation of CAR-bearing immune cells for effective tumor control.
Through our partnership with Simnova Biotherapeutics, we are working to develop the China market for a number of multiple potential therapeutics in the area of oncology to deliver on the promise of circular RNA therapies.replacement
Orna’s in situ CAR therapy (isCAR™) combines oRNA™ technology with our proprietary LNPs to create modified immune cells within a patient, no lymphodepletion required. Unlike existing ex vivo CAR-T therapies, our isCAR™ program generates CAR-T, CAR-NK and CAR-Mac cells at once, and is truly off-the-shelf. This easily redosable format allows for reliable dose control and consistent generation of CAR-bearing immune cells for effective tumor control.
Through our partnership with Simnova Biotherapeutics, we are working to develop the China market for a number of multiple potential therapeutics in the area of oncology to deliver on the promise of circular RNA therapies.